| scholarly article | Q13442814 |
| P50 | author | Christian Torp-Pedersen | Q33310590 |
| Gunnar Hilmar Gislason | Q33310632 | ||
| Anne-Marie Schjerning Olsen | Q33310643 | ||
| Peter Riis Hansen | Q40522490 | ||
| Søren Jacobsen | Q61093861 | ||
| Ole Rintek Madsen | Q90617605 | ||
| Jesper Lindhardsen | Q116772509 | ||
| Ole Ahlehoff | Q116772512 | ||
| P2860 | cites work | Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies | Q21144617 |
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry | Q30779443 | ||
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Validation of rheumatoid arthritis diagnoses in health care utilization data | Q33827617 | ||
| Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. | Q33908100 | ||
| Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study | Q34183822 | ||
| Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 | ||
| Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis | Q34553523 | ||
| Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 | ||
| Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study | Q35815364 | ||
| Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. | Q37079259 | ||
| Role of inflammation in atherosclerosis associated with rheumatoid arthritis | Q37300182 | ||
| Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study | Q37422931 | ||
| Trend in mortality after stroke with atrial fibrillation | Q38464677 | ||
| Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis | Q38489191 | ||
| Predicting mortality in patients with rheumatoid arthritis | Q40582797 | ||
| Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study | Q43540832 | ||
| Validity of stroke diagnoses in a National Register of Patients | Q45086079 | ||
| Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis | Q45129989 | ||
| Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis | Q45333297 | ||
| Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis | Q46068912 | ||
| The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people | Q46668679 | ||
| Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. | Q52864698 | ||
| Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction | Q57260454 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| rheumatoid arthritis | Q187255 | ||
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 1515-1521 | |
| P577 | publication date | 2013-06-08 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study | |
| P478 | volume | 73 |
| Q90478695 | Adjunctive Chinese Herbal Products Therapy Reduces the Risk of Ischemic Stroke Among Patients With Rheumatoid Arthritis |
| Q64254840 | Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q91776881 | Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
| Q38941017 | Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks |
| Q58609925 | Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis |
| Q92464675 | Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment |
| Q35121150 | Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions |
| Q26738461 | Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach |
| Q26744334 | Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps |
| Q54115193 | Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. |
| Q88802673 | Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample |
| Q36241707 | Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. |
| Q33750044 | HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis |
| Q38962092 | Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis? |
| Q63865703 | Impact of red meat, processed meat and fibre intake on risk of late-onset chronic inflammatory diseases: prospective cohort study on lifestyle factors using the Danish 'Diet, Cancer and Health' cohort (PROCID-DCH): |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q89449421 | Inflammation: NSAIDs and cardiovascular risk in arthritis |
| Q40709084 | Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? |
| Q28547208 | Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study |
| Q88310736 | Managing premature atherosclerosis in patients with chronic inflammatory diseases |
| Q40976343 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal |
| Q35124825 | Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. |
| Q57751622 | Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis |
| Q38290838 | The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. |
| Q35135831 | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. |
| Q93270483 | Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients |
| Q38663003 | Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. |
| Q87907461 | [Coxibs] |
Search more.